CCS
CELG

Crosspoint Capital Strategies’s Celgene Corp CELG Stock Holding History

Crosspoint Capital Strategies’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-304
Closed -$34K – 1046
2015
Q4 		$34K Buy
304
+217
+249% +$25.1K 0.01% 502
2015
Q3 		$9K Sell
87
-1,089
-93% -$135K 0.01% 432
2015
Q2 		$136K Sell
1,176
-26,687
-96% -$3.05M 0.04% 237
2015
Q1 		$3.21M Buy
+27,863
New +$3.33M 1.55% 29
2014
Q2 		– Sell
-1,000
Closed -$70K – 725
2014
Q1 		$70K Buy
1,000
+200
+25% +$15.8K 0.03% 228
2013
Q4 		$65K Buy
+800
New +$63.3K 0.02% 241

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Crosspoint Capital Strategies's CELG Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Celgene Corp (CELG) in Q1 2016, closing a stake of 304 shares — an estimated $34K sold.

Crosspoint Capital Strategies first reported a position in CELG in Q4 2013 and held it in 6 quarters. The position peaked at $3.21M in Q1 2015. 1,224 funds tracked by Wall St. Rank hold CELG as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Celgene Corp position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 304 Celgene Corp shares in Q1 2016, an estimated $34K.
  • Crosspoint Capital Strategies first reported a position in Celgene Corp in Q4 2013 and held it in 6 quarters.
  • Crosspoint Capital Strategies's Celgene Corp position peaked at $3.21M in Q1 2015.
  • 1,224 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.